Are new agents needed to treat RA?
Open Access
- 1 October 2009
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 5 (10), 521-522
- https://doi.org/10.1038/nrrheum.2009.197
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Prevalence of and predictive factors for sustained disease‐modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohortsArthritis & Rheumatism, 2009
- Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritisArthritis & Rheumatism, 2009
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnnals Of The Rheumatic Diseases, 2008